Table 3.
Viral suppression according to TLD coverage by age.
| Variables | Overall† | Viral load‡ | OR (95% CI) | P value* | ||
|---|---|---|---|---|---|---|
| N = 9034 | < 1000 copies/mL; N = 8112 (89.8%) | ≥ 1000 copies/mL; N = 822 (10.2%) | ||||
| Gender | ||||||
| Male | TDF + 3TC + DTG | 2003 (79.9) | 1794 (89.5) | 210 (10.5) | 1 | <.0001 |
| Other ART | 505 (20.1) | 389 (77.2) | 115 (22.8) | 0.39 (0.30–0.50) | ||
| Female | TDF + 3TC + DTG | 5114 (78.4) | 4743 (92.7) | 371 (7.3) | 1 | <.0001 |
| Other ART | 1412 (21.6) | 1186 (84.0) | 226 (16.0) | 0.41 (0.34–0.49) | ||
| Age categories | ||||||
| Children | TDF + 3TC + DTG | 82 (36.9) | 60 (73.2) | 22 (26.8) | 1 | .043 |
| Other ART | 140 (63.1) | 83 (59.7) | 56 (40.3) | 0.54 (0.29–0.98) | ||
| Adolescents | TDF + 3TC + DTG | 138 (60.8) | 111 (80.4) | 27 (19.6) | 1 | .010 |
| Other ART | 89 (39.2) | 58 (65.2) | 31 (34.8) | 0.45 (0.24–0.83) | ||
| Adults | TDF + 3TC + DTG | 6897 (80.3) | 6364 (92.3) | 533 (7.7) | 1 | <.0001 |
| Other ART | 1688 (19.7) | 1437 (85.1) | 251 (14.9) | 0.47 (0.40–0.56) | ||
Other ART: ARV [ABC + 3TC + EFV (n = 13), ABC + 3TC + NVP (n = 2), AZT + 3TC + EFV (n = 36), AZT + 3TC + NVP (n = 14), TDF + 3TC + NVP (n = 51), TDF + 3TC + EFV (1511)], Lopinavir based (n = 173) and atazanavir based (n = 117).
3TC = lamivudine, ART = antiretroviral therapy, ARV = antiretroviral, ATVr = ritonavir boosted atazanavir, CI = confidence interval, DTG = dolutegravir, EFV = efavirenz, IQR = interquartile range, LPVr = ritonavir boosted lopinavir, OR = odds ratioTDF = tenofovir disoproxil fumarate, TLD = Tenofovir + Lamivudine + Dolutegravir.
P value for virological success at < 1000 copies/M.
Percentages in this column represent column percentage.
Percentages in this column represents row percentage.